Racotumomab Biosimilar – Anti-Idiotope of anti-(N-glycolylneuraminic acid (NeuGc,NGNA) -gangliosides GM3) Mus musculus IgM-kappa monoclonal antibody P3 mAb – Research Grade

Description of Racotumomab Biosimilar - Anti-Idiotope of anti-(N-glycolylneuraminic acid (NeuGc,NGNA) -gangliosides GM3) Mus musculus IgM-kappa monoclonal antibody P3 mAb - Research Grade

Title: Racotumomab Biosimilar – A Novel Anti-Idiotope Antibody Targeting NeuGc-NGNA Gangliosides

Introduction:

Racotumomab Biosimilar, also known as P3 mAb, is a research grade, anti-idiotope antibody that specifically targets the N-glycolylneuraminic acid (NeuGc) containing gangliosides, particularly GM3, on the surface of tumor cells. This monoclonal antibody (mAb) is derived from Mus musculus (mouse) IgM-kappa and has shown promising results in preclinical and clinical studies as a potential therapeutic agent for various types of cancer.

Structure:

P3 mAb is a mouse-derived IgM-kappa monoclonal antibody with a molecular weight of approximately 900 kDa. It is composed of five immunoglobulin (Ig) heavy chains and five light chains, which are connected by disulfide bonds. The variable regions of the heavy and light chains are responsible for the specificity of P3 mAb towards NeuGc-containing gangliosides.

Activity:

The main target of P3 mAb is the NeuGc-containing ganglioside GM3, which is overexpressed on the surface of many tumor cells, including breast, lung, and colon cancer cells. P3 mAb binds to GM3 with high affinity, leading to the activation of the immune system and subsequent destruction of the tumor cells. Additionally, P3 mAb has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), further enhancing its anti-tumor activity.

Application:

The unique specificity of P3 mAb towards NeuGc-containing gangliosides makes it a promising therapeutic agent for various types of cancer. Preclinical studies have demonstrated the efficacy of P3 mAb in inhibiting tumor growth and metastasis in animal models. In a phase I clinical trial, P3 mAb showed a good safety profile and promising results in patients with advanced breast cancer, leading to the development of a phase II/III trial for this indication.

Moreover, P3 mAb has also shown potential as an adjuvant therapy in combination with other anti- cancer treatments. In a preclinical study, P3 mAb enhanced the anti-tumor activity of chemotherapy in a mouse model of colon cancer. This suggests that P3 mAb could be used in combination with other therapies to improve treatment outcomes.

Conclusion:

Racotumomab Biosimilar, or P3 mAb, is a novel anti-idiotope antibody that specifically targets NeuGc-containing gangliosides, particularly GM3, on the surface of tumor cells. Its unique structure and activity make it a promising therapeutic agent for various types of cancer, with potential applications as both a monotherapy and in combination with other treatments. Further clinical studies are needed to fully evaluate the efficacy and safety of P3 mAb, but it holds great promise as a potential therapeutic target for cancer treatment.